MA47130A - Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations - Google Patents

Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations

Info

Publication number: MA47130A
Authority: MA; Morocco
Prior art keywords: human; specifically binding; antibodies specifically; antibodies; binding
Prior art date: 2016-12-21

Application number

MA047130A

Other languages

English (en)

Inventor

Adam William Clarke

Anthony Gerard Doyle

David Jose Simon Laine

Matthew Pollard

Lynn Dorothy Poulton

Original Assignee

Cephalon Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-12-21

Filing date

2017-12-21

Publication date

2019-10-30

2017-12-21 Application filed by Cephalon Inc filed Critical Cephalon Inc

2019-10-30 Publication of MA47130A publication Critical patent/MA47130A/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5443—IL-15

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Obesity (AREA)
Physics & Mathematics (AREA)
Physical Education & Sports Medicine (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Microbiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)

MA047130A 2016-12-21 2017-12-21 Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations MA47130A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201662437143P	2016-12-21	2016-12-21

Publications (1)

Publication Number	Publication Date
MA47130A true MA47130A (fr)	2019-10-30

Family

ID=62627610

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA047130A MA47130A (fr)	2016-12-21	2017-12-21	Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations

Country Status (19)

Country	Link
US (2)	US11267883B2 (fr)
EP (1)	EP3558369B1 (fr)
JP (2)	JP7155126B2 (fr)
KR (2)	KR20190097094A (fr)
CN (1)	CN110234349B (fr)
AR (1)	AR110414A1 (fr)
AU (2)	AU2017382850B2 (fr)
BR (1)	BR112019012570A8 (fr)
CA (1)	CA3046387A1 (fr)
CL (1)	CL2019001729A1 (fr)
EA (1)	EA201991514A1 (fr)
IL (1)	IL267113B2 (fr)
MA (1)	MA47130A (fr)
MX (2)	MX2019007357A (fr)
PE (1)	PE20191497A1 (fr)
PH (1)	PH12019501453A1 (fr)
UA (1)	UA126284C2 (fr)
WO (1)	WO2018119246A1 (fr)
ZA (1)	ZA201903848B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN105637097A (zh)	2013-08-05	2016-06-01	特韦斯特生物科学公司	从头合成的基因文库
CA2975852A1 (fr)	2015-02-04	2016-08-11	Twist Bioscience Corporation	Procedes et dispositifs pour assemblage de novo d'acide oligonucleique
US9981239B2 (en)	2015-04-21	2018-05-29	Twist Bioscience Corporation	Devices and methods for oligonucleic acid library synthesis
JP6982362B2 (ja)	2015-09-18	2021-12-17	ツイストバイオサイエンスコーポレーション	オリゴ核酸変異体ライブラリーとその合成
WO2017053450A1 (fr)	2015-09-22	2017-03-30	Twist Bioscience Corporation	Substrats flexibles pour synthèse d'acide nucléique
JP6871364B2 (ja)	2016-09-21	2021-05-12	ツイストバイオサイエンスコーポレーション	核酸に基づくデータ保存
SG11201907713WA (en)	2017-02-22	2019-09-27	Twist Bioscience Corp	Nucleic acid based data storage
WO2018231864A1 (fr)	2017-06-12	2018-12-20	Twist Bioscience Corporation	Méthodes d'assemblage d'acides nucléiques continus
US10696965B2 (en)	2017-06-12	2020-06-30	Twist Bioscience Corporation	Methods for seamless nucleic acid assembly
AU2018328847A1 (en)	2017-09-11	2020-04-23	Twist Bioscience Corporation	GPCR binding proteins and synthesis thereof
CA3079613A1 (fr)	2017-10-20	2019-04-25	Twist Bioscience Corporation	Nano-puits chauffes pour la synthese de polynucleotides
SG11202006460SA (en)	2018-01-04	2020-08-28	Twist Bioscience Corp	Dna-based digital information storage
WO2019222706A1 (fr)	2018-05-18	2019-11-21	Twist Bioscience Corporation	Polynucléotides, réactifs, et procédés d'hybridation d'acides nucléiques
US11828385B2 (en)	2018-12-25	2023-11-28	Ntn Corporation	Flow control valve seal and flow control valve device
CA3131691A1 (fr)	2019-02-26	2020-09-03	Twist Bioscience Corporation	Banques d'acides nucleiques variants pour l'optimisation d'anticorps
AU2020291012A1 (en)	2019-06-12	2021-12-16	AskGene Pharma, Inc.	Novel IL-15 prodrugs and methods of use thereof
CN114729342A (zh)	2019-06-21	2022-07-08	特韦斯特生物科学公司	基于条形码的核酸序列装配
CA3155630A1 (fr)	2019-09-23	2021-04-01	Twist Bioscience Corporation	Bibliotheques d'acides nucleiques variants pour des anticorps a domaine unique
WO2021061829A1 (fr)	2019-09-23	2021-04-01	Twist Bioscience Corporation	Banques d'acides nucléiques variants pour crth2
WO2021119193A2 (fr) *	2019-12-09	2021-06-17	Twist Bioscience Corporation	Bibliothèques de variants d'acides nucléiques pour les récepteurs d'adénosine
US12202905B2 (en)	2021-01-21	2025-01-21	Twist Bioscience Corporation	Methods and compositions relating to adenosine receptors
CN116655771A (zh) *	2021-05-28	2023-08-29	苏州复融生物技术有限公司	一种新型白介素15突变体多肽的开发及其应用
WO2024028448A1 (fr)	2022-08-04	2024-02-08	Calypso Biotech Sa	Inhibiteurs d'il-15 utiles pour le traitement de la dermatite atopique
CN118894934A (zh) *	2023-05-05	2024-11-05	北京智仁美博生物科技有限公司	抗人il-15的抗体及其用途
CN117209605B (zh) *	2023-11-09	2024-01-30	北京百普赛斯生物科技股份有限公司	特异性结合il-15的抗体及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5795966A (en)	1995-02-22	1998-08-18	Immunex Corp	Antagonists of interleukin-15
MX353234B (es)	1999-01-15	2018-01-08	Genentech Inc	Variantes de polipeptidos con función efectora alterada.
DK1355919T3 (da)	2000-12-12	2011-03-14	Medimmune Llc	Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
US7132510B2 (en)	2000-12-29	2006-11-07	Bio-Technology General (Israel) Ltd.	Specific human antibodies for selective cancer therapy
SI1425389T1 (sl) *	2001-08-23	2012-02-29	Genmab As	Humana protitelesa, specifična za interlevkin 15 (IL-15)
US7247304B2 (en) *	2001-08-23	2007-07-24	Genmab A/S	Methods of treating using anti-IL-15 antibodies
US7329405B2 (en) *	2001-08-23	2008-02-12	Genmab A/S	Human antibodies specific for interleukin 15 (IL-15)
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US7217797B2 (en)	2002-10-15	2007-05-15	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004050683A2 (fr) *	2002-12-02	2004-06-17	Abgenix, Inc.	Anticorps agissant sur le facteur de necrose des tumeurs (tnf) et leurs utilisation
RS20050724A (en) *	2003-02-26	2007-11-15	Genmab A/S.,	Human antibodies specific for interleukin 15(il-15)
TW200619227A (en) *	2004-08-11	2006-06-16	Hoffmann La Roche	Mutant interleukin-15-containing compositions and suppression of an immune response
JP4942644B2 (ja)	2005-02-28	2012-05-30	株式会社抗体研究所	抗ＩｇＳＦ４抗体及びその利用
AU2006244885B2 (en) *	2005-05-09	2011-03-31	E. R. Squibb & Sons, L.L.C.	Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
SG10201509853UA (en)	2007-06-01	2015-12-30	Omt Inc	Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
AR068767A1 (es)	2007-10-12	2009-12-02	Novartis Ag	Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
EP3871497B1 (fr) *	2009-07-08	2024-02-28	Kymab Limited	Modèles de rongeurs et molécules thérapeutiques
RU2012119788A (ru) *	2009-10-15	2013-11-20	Эбботт Лэборетриз	Связывающие il-1 белки
EP4012714A1 (fr)	2010-03-23	2022-06-15	Iogenetics, LLC.	Procédés bioinformatiques pour déterminer la liaison de peptides
MX341309B (es) *	2010-07-20	2016-08-12	Cephalon Australia Pty Ltd	Anticuerpos especificos del heterodimero de anti-il-23.
JP5820688B2 (ja)	2011-03-23	2015-11-24	株式会社Kri	多糖類の溶解に用いられる溶媒ならびに該溶媒を用いた成形体および多糖類誘導体の製造方法
BR112014003999A2 (pt) *	2011-08-23	2017-06-13	Roche Glycart Ag	anticorpo isolado que se liga a um epítopo próximo da membrana de mcsp humano, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de indivíduos portadores de câncer, método de undução da lise celular em indivíduos e teste imuno-histoquímico de mcsp
EP3559049A4 (fr) *	2011-10-28	2019-12-04	Teva Pharmaceuticals Australia Pty Ltd	Produits de recombinaison de polypeptide et utilisations de ceux-ci
KR20150122761A (ko) *	2013-02-26	2015-11-02	로슈 글리카트 아게	Ｔ 세포 활성화 항원 결합 분자
UA118028C2 (uk) *	2013-04-03	2018-11-12	Рош Глікарт Аг	Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP2963057A1 (fr) *	2014-07-02	2016-01-06	Calypso Biotech SA	Anticorps pour IL-15
NZ736026A (en)	2015-03-31	2023-02-24	Medimmune Ltd	A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
CN109311972A (zh) *	2016-06-15	2019-02-05	美国安进公司	用于治疗乳糜泻、非乳糜泻麸质敏感和难治性乳糜泻的方法和组合物
CA3039930A1 (fr)	2016-10-14	2018-04-19	Xencor, Inc.	Proteines de fusion heterodimeres bispecifiques contenant des proteines de fusion fc il-15/il-15ralpha et des fragments d'anticorps pd-1

2017
- 2017-12-21 AU AU2017382850A patent/AU2017382850B2/en active Active
- 2017-12-21 UA UAA201908753A patent/UA126284C2/uk unknown
- 2017-12-21 IL IL267113A patent/IL267113B2/en unknown
- 2017-12-21 BR BR112019012570A patent/BR112019012570A8/pt unknown
- 2017-12-21 EA EA201991514A patent/EA201991514A1/ru unknown
- 2017-12-21 AR ARP170103614A patent/AR110414A1/es unknown
- 2017-12-21 CN CN201780079926.6A patent/CN110234349B/zh active Active
- 2017-12-21 PE PE2019001283A patent/PE20191497A1/es unknown
- 2017-12-21 KR KR1020197019269A patent/KR20190097094A/ko not_active Abandoned
- 2017-12-21 KR KR1020237031493A patent/KR102706743B1/ko active Active
- 2017-12-21 MA MA047130A patent/MA47130A/fr unknown
- 2017-12-21 WO PCT/US2017/067917 patent/WO2018119246A1/fr unknown
- 2017-12-21 JP JP2019533652A patent/JP7155126B2/ja active Active
- 2017-12-21 US US16/471,616 patent/US11267883B2/en active Active
- 2017-12-21 MX MX2019007357A patent/MX2019007357A/es unknown
- 2017-12-21 CA CA3046387A patent/CA3046387A1/fr active Pending
- 2017-12-21 EP EP17883800.9A patent/EP3558369B1/fr active Active
2019
- 2019-06-13 ZA ZA2019/03848A patent/ZA201903848B/en unknown
- 2019-06-19 MX MX2023014081A patent/MX2023014081A/es unknown
- 2019-06-20 CL CL2019001729A patent/CL2019001729A1/es unknown
- 2019-06-21 PH PH12019501453A patent/PH12019501453A1/en unknown
2022
- 2022-01-05 US US17/647,082 patent/US20220127352A1/en active Pending
- 2022-10-05 JP JP2022161059A patent/JP2022176324A/ja active Pending
2025
- 2025-02-20 AU AU2025201185A patent/AU2025201185A1/en active Pending

Also Published As

Publication number	Publication date
KR20190097094A (ko)	2019-08-20
JP2020501583A (ja)	2020-01-23
PE20191497A1 (es)	2019-10-21
CA3046387A1 (fr)	2018-06-28
AU2025201185A1 (en)	2025-03-13
JP7155126B2 (ja)	2022-10-18
MX2023014081A (es)	2023-12-06
BR112019012570A8 (pt)	2023-01-24
PH12019501453A1 (en)	2020-06-15
AU2017382850B2 (en)	2024-11-21
EA201991514A1 (ru)	2019-12-30
MX2019007357A (es)	2019-09-05
IL267113B2 (en)	2024-09-01
US20200270339A1 (en)	2020-08-27
US11267883B2 (en)	2022-03-08
AU2017382850A1 (en)	2019-07-04
CL2019001729A1 (es)	2019-09-13
KR102706743B1 (ko)	2024-09-19
CN110234349A (zh)	2019-09-13
AR110414A1 (es)	2019-03-27
EP3558369A1 (fr)	2019-10-30
WO2018119246A1 (fr)	2018-06-28
UA126284C2 (uk)	2022-09-14
JP2022176324A (ja)	2022-11-25
BR112019012570A2 (pt)	2019-11-26
US20220127352A1 (en)	2022-04-28
KR20230135691A (ko)	2023-09-25
EP3558369A4 (fr)	2020-09-09
EP3558369B1 (fr)	2025-03-26
IL267113A (en)	2019-08-29
ZA201903848B (en)	2023-02-22
CN110234349B (zh)	2024-03-22
IL267113B1 (en)	2024-05-01

Publication	Publication Date	Title
MA47130A (fr)	2019-10-30	Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations
FR24C1023I1 (fr)	2024-07-26	Anticorps thérapeutiques et leurs utilisations
MA49457A (fr)	2020-04-29	Molécules d'anticorps se liant à cd73 et leurs utilisations
MA52459A (fr)	2021-03-10	Anticorps se liant spécifiquement à pd-1 et leurs méthodes d'utilisation
EP3817769A4 (fr)	2022-03-30	Anticorps anti-cd47 humains et leurs utilisations
EP3383916A4 (fr)	2019-09-11	Anticorps anti-cd73 et leurs utilisations
MA52773A (fr)	2021-04-14	Anticorps anti-cd3 et leurs utilisations
MA44723A (fr)	2019-02-27	Anticorps agonistes se liant au cd40 humain et leurs utilisations
EP3370768A4 (fr)	2019-07-24	Anticorps se liant spécifiquement à pd-1 et leurs utilisations
EP3389702A4 (fr)	2019-08-14	Anticorps anti-lag-3 et leurs utilisations
EP3362479A4 (fr)	2019-05-15	Agents de type anticorps spécifiques de l'antigène cd19 humain et leurs utilisations
MA49687A (fr)	2020-06-03	Anticorps anti-ctla-4 et leurs utilisations
MA47789A (fr)	2020-01-22	Anticorps anti-phf-tau et leurs utilisations
MA43308A (fr)	2018-10-03	Molécules d'anticorps se liant à april et leurs utilisations
EP3426288A4 (fr)	2019-10-30	Anticorps anti-pacap et leurs utilisations
EP3370770A4 (fr)	2019-06-12	Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MA45123A (fr)	2019-04-10	Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA42808A (fr)	2018-07-25	Anticorps de liaison à l'il-8 et leurs utilisations
MA45125A (fr)	2021-06-02	Anticorps anti-alpha-synucléine et leurs utilisations
MA49886A (fr)	2020-06-24	Anticorps anti-par2 et leurs utilisations
EP3328994A4 (fr)	2019-04-17	Protéines de liaison d'antigène ciblant cd56 et leurs utilisations
EP2961774A4 (fr)	2016-10-26	Anticorps d'alpha-synucléine et leurs utilisations
MA45233A (fr)	2019-04-17	Anticorps anti-gitr et leurs utilisations
MA46704A (fr)	2019-09-11	Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA44665A (fr)	2019-02-20	Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques